Osel Inc | Harnessing the microbiome improving health Osel filed a new IND for CBM588 oncology indications in early 2024 and has begun a Phase 1 dose escalation trial in advanced kidney cancer with a new capsule formulation of CBM588 at the City of Hope Comprehensive Cancer Center
About Osel Osel’s mission is to develop and commercialize a broad portfolio of Live Biotherapeutic Products (LBPs) that prevent or treat conditions resulting from disruptions of the human microbiome
NEWS - Osel Inc About Osel, Inc Osel Inc , a privately held biopharmaceutical company based in Mountain View, California, is focused on the development and commercialization of a portfolio of LBPs to prevent or treat medical conditions resulting from disruption of the human microbiome (dysbiosis)
Women’s Health - Osel Inc To address this unmet medical need, Osel developed a proprietary Live Biotherapeutic Product (LBP), called LACTIN-V that contains the protective vaginal strain, Lactobacillus crispatus CTV-05
Clinical Pipeline | Osel Inc Osel’s LACTIN-V is a live biotherapeutic product addressing women’s health disorders LACTIN-V is under development for preventing recurrent BV and preterm birth
Our Science - Osel Inc Osel has pioneered the development of live biotherapeutics products that prevent disease by treating the dysbiosis underlying these conditions Our research and development is focused on disorders of the genitourinary and gastrointestinal tracts, and cancer
Frequently Asked Questions - Osel Inc LACTIN-V is a live biotherapeutic product (LBP) containing the live bacterium Lactobacillus crispatus CTV-05, a naturally occurring member of the human vaginal microbiome LBP is defined by the FDA as a biologic drug that contains live microorganisms for the prevention, treatment, or cure of a disease or condition of human beings, and not a vaccine
LACTIN-V - Osel Inc Osel’s LACTIN-V is a live biotherapeutic product addressing women’s health disorders It incorporates a single species and strain of Lactobacillus that is part of the natural microbiome of healthy women and that has been selected for features that restore health and prevent recurrence of infection
MIYA-BM - Osel Inc Osel plans to conduct Phase 2 and Phase 3 trials and file a Biologic License Application (BLA) with FDA Osel is also intends to evaluate the therapeutic potential of MIYA-BM for the treatment of IBS and for inflammatory bowel disease, such as Ulcerative Colitis (UC)
MucoCept Technology Platform - Osel Inc Over the past several years, Osel has made substantial progress in the development of this novel topical microbicide (see more in Publications) MucoCept has undergone a positive “proof of concept” study